We have located links that may give you full text access.
COMPARATIVE STUDY
JOURNAL ARTICLE
Immediate skin test reactivity to Food and Drug Administration-approved standardized extracts.
Journal of Allergy and Clinical Immunology 1990 November
In an effort to determine whether recently introduced Food and Drug Administration-approved standardized extracts produce clinically appropriate responses in a population, 200 subjects were skin prick tested (SPT). Thirteen extracts (10 pollens, two house dust (HD) mites and cat) were tested in three groups of subjects, 50 with a history of asthma or allergic rhinitis (AL), 50 without asthma or perennial or seasonal allergic rhinitis but with a positive immediate family history for these conditions (FAL), and 100 subjects without a personal or family history for these conditions (NAL). An SPT mean wheal diameter greater than or equal to 3 mm was considered positive. Ninety percent (95% confidence interval [CI], 82% to 98%) of AL subjects had at least one positive SPT. Forty-six percent of FAL subjects (95% CI, 30% to 58%) and 29% of NAL subjects (95% CI, 20% to 38%) had at least one positive SPT. More FAL than NAL subjects had at least one SPT (p less than 0.05), and FAL subjects had more positive SPTs than NAL subjects (p less than 0.05), further supporting the genetic regulation of allergen-specific IgE production. Of the five AL subjects with no SPT wheal greater than or equal to 3 mm, three subjects were available for intradermal tests. Thirteen nonstandardized allergens similar to allergens used for SPT were applied intradermally in each of these three subjects and were all negative. Compared with history, an SPT wheal greater than or equal to 3 mm to cat produced a sensitivity of 0.90, a specificity of 0.90, and diagnostic accuracy of 0.90. Tenfold dilutions of pollens and cat reduced sensitivity without significantly improving specificity.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app